PNC Financial Services Group Inc. Sells 241,073 Shares of Pfizer Inc. $PFE

PNC Financial Services Group Inc. reduced its position in Pfizer Inc. (NYSE:PFE) by 3.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,192,560 shares of the biopharmaceutical company’s stock after selling 241,073 shares during the quarter. PNC Financial Services Group Inc. owned 0.13% of Pfizer worth $179,095,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of PFE. Horizon Financial Services LLC raised its holdings in shares of Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 645 shares during the period. YANKCOM Partnership purchased a new position in Pfizer during the 4th quarter valued at $28,000. Grey Fox Wealth Advisors LLC bought a new position in Pfizer in the 3rd quarter valued at $29,000. HFM Investment Advisors LLC grew its position in Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the last quarter. Finally, Darwin Wealth Management LLC purchased a new stake in Pfizer in the second quarter worth $32,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of Pfizer stock opened at $25.78 on Thursday. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The stock’s fifty day moving average price is $26.91 and its 200-day moving average price is $26.22. The firm has a market cap of $146.91 billion, a P/E ratio of 19.68 and a beta of 0.35. Pfizer Inc. has a 12 month low of $22.81 and a 12 month high of $28.75.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Daiwa Securities Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price for the company. in a research note on Thursday, February 12th. Morgan Stanley lifted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Wolfe Research reaffirmed an “underperform” rating and set a $26.00 target price on shares of Pfizer in a research report on Thursday, May 14th. Finally, Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price on the stock in a research report on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $28.61.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer advanced its new 25-strain pneumococcal vaccine into pivotal testing after strong Phase 2 infant data showed a much stronger immune response than Prevnar 20, raising the chance of a future growth driver. Reuters article
• Positive Sentiment: Pfizer also highlighted long-term oncology expansion around Padcev, biosimilars, and late-stage pipeline assets, which could help offset pressure from legacy drugs and improve future revenue visibility. Zacks article
• Neutral Sentiment: Several articles repeated the same pipeline themes, reinforcing investor attention on vaccine and oncology programs rather than introducing entirely new developments. Business Wire article
• Neutral Sentiment: One commentary piece compared Pfizer’s dividend and valuation profile with Johnson & Johnson, noting PFE’s low valuation and high yield but also weaker consistency versus JNJ; this may support income-focused investors, but it is not a direct operating catalyst. Seeking Alpha article
• Negative Sentiment: The J&J comparison underscores ongoing concerns about Pfizer’s relative growth consistency, suggesting the stock may still trade at a discount until management proves the pipeline can deliver more durable earnings growth. Seeking Alpha article

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.